Poster presented at ASH 2022 evaluating a new therapeutic approach for patients with B-cell malignancies who received prior BTKi treatment and became intolerant.

Poster presented at ASH 2022 describing the potential for combining BCL2i and BTKi in patients with non-Hodgkin’s lymphoma (NHL), including separate cohorts for mantle cell lymphoma (MCL) and Waldenström’s macroglobulinemia (WM).

BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to treat cancer. Get up to date with the BeiGene hematology pipeline and clinical trials.

Factsheet describing the treatment of Waldenström’s macroglobulinemia (WM) by inhibiting BTK.

Slide kit describing the treatment of Waldenström’s macroglobulinemia (WM) by inhibiting BTK.